Work

Weighing the Risks and Benefits of Microdosing Tirzepatide Vials

Year: 2026

Type: article

Abstract: Tirzepatide for chronic weight management is available in single-use autoinjector pens, multi-dose pens, and single-dose vials (1).Tirzepatide multi-dose vials are approved but not yet commercially available (1).We previously described the rationale for microdosing semaglutide and tirzepatide in multi-dose pens (2,3).The same rationale can be applied to tirzepatide vials.

Source: Diabetes Obesity and Cardiometabolic CARE

DOI: 10.2337/doc26-0083

Authors: Anne M. Komé, Shelby Tungate Lopez, Alissa V. Russell, Klara R. Klein

Institution: University of North Carolina at Chapel Hill

Language: English

Topic: Pharmacology and Obesity Treatment

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Center for Advancing Translational Sciences